- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials
A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based therapy in patients with HIV, showing noninferiority with over 90% of patients maintaining viral suppression without excess toxicity.
EP: 1.HIV Viral Suppression: Clinical Significance and Impact on Patient Outcomes
EP: 2.Changing Patient Demographics in HIV and Impacts of Polypharmacy on Treatment
EP: 3.Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials
EP: 4.HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations
EP: 5.Long-Acting HIV Therapies: Real-World Data and Clinical Application
EP: 6.CD4 T-cell and Lymphocyte Monitoring: Clinical Significance in HIV Treatment
EP: 7.CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments
New Drug Combination - Doravirine and Islatravir
Key Themes:
- Novel Combination Therapy: A late-breaker study presented at the Conference on Retroviruses and Opportunistic Infections showed noninferiority of doravirine (nonnucleoside reverse transcriptase inhibitor [NNRTI]) plus islatravir (nucleoside reverse transcriptase translocation inhibitor [NRTTI]) compared with a standard bictegravir-based regimen.
- Patient Selection Criteria: The study enrolled patients suppressed for at least 3 months on bictegravir with T-cell counts greater than 50 and no prior virologic failure.
- Safety Monitoring: Special attention was given to effects on CD4 counts and lymphocytes, as earlier studies with islatravir showed potential toxicity.
- Hepatitis B Considerations: The new combination lacks anti–hepatitis B virus (HBV) activity, requiring HBV screening before switching.
Notable Insights From Dr Sharon Walmsley:
- The doravirine/islatravir combination maintained viral suppression in more than 90% of patients over 144 weeks.
- No cases of treatment resistance were observed in participants experiencing virologic failure.
- Unlike in earlier studies, no evidence of lymphopenia or CD4 cell count reduction was observed with the islatravir component.
Only 2% to 3% of patients discontinued due to adverse events, indicating good tolerability.
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds
August 5th 2025Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.
Read More
